Background: Docetaxel (Taxotere) improve survival and prostate-specific antigen (PSA) response rates in patients with metastatic castrate-resistant prostate cancer (CRPC). We studied the combination of PI-88, an inhibitor of angiogenesis and heparanase activity, and docetaxel in chemotherapy-naive CRPC.
introduction Docetaxel (Taxotere, Sanofi-Aventis, Bridgewater, NJ), a semisynthetic taxane that inhibits microtubular depolymerisation, has been shown to improve survival in patients with metastatic castrate-resistant prostate cancer (CRPC). In the TAX 327 study, three-weekly docetaxel doses (75 mg/m 2 i.v.) and prednisone demonstrated an improvement in median survival of 2.5 months, improvement in prostatespecific antigen (PSA) response rate, in pain control and quality of life, compared with mitoxantrone/prednisone [1] . Similar survival findings were observed in a parallel phase III study using docetaxel with estramustine (Southwest Oncology Group 9916); however, grade 3 toxicity was prominent using this combination [2] . These studies have established three-weekly docetaxel doses as the new standard of care for patients with metastatic CRPC. Clinical trials of combinations of docetaxel with novel biologic and antiangiogenic agents are underway in an effort to further improve outcomes of patients with CRPC.
Increased tumour angiogenesis has been shown to predict for a more malignant phenotype with a greater likelihood of metastatic disease [2, 3] . The extracellular matrix of tumours is a complex network of heparan sulfate proteoglycans (HSPGs), collagen, laminin and fibronectin. This network acts as a storage depot for many heparin-binding growth factors including angiogenic factors, such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF) and chemokines [3] . HSPGs exist on cell surfaces facilitating cell signalling and growth factor binding. Heparanase is a ubiquitous endoglycosidase that specifically cleaves HSPGs facilitating angiogenesis through growth factor release and metastasis by enhancing cell invasion, migration, intravasation and extravasation [3] . In vitro studies using prostate cancer cell lines have demonstrated elevated heparanase enzyme activity in malignant versus benign prostate tissue, implying a role in the malignant behaviour of prostate cancers [3] [4] [5] . Therefore, the heparanase enzyme is a potential target for anticancer therapy.
PI-88 is a mixture of highly sulfated oligosaccharides derived from the yeast Pichia (Hansenula) holstii NRRL Y-2488 and is a potent inhibitor of heparanase. PI-88 has shown antitumour activity in vitro and in vivo by inhibiting VEGF and fibroblast growth factor as well as stimulating the release of tissue factor pathway inhibitors [6, 7] . Preclinical animal studies have demonstrated additive tumour growth inhibition with a number of cytotoxic agents, in particular cisplatin and paclitaxel [8, 9] . Furthermore, distribution studies have demonstrated that the drug has a high propensity for bone, commonest site of metastasis in prostate cancer [10] . Therefore, men with metastatic CRPC would be a suitable population to explore combination of PI-88 and chemotherapy.
Earlier studies of PI-88, used as monotherapy and in combination with chemotherapy, indicate that PI-88 is well tolerated. Thrombocytopenia, in some cases immune mediated, has also been observed in patients treated with PI-88. Other safety risks included injection site reactions (haemorrhage, bruising, irritation, pain, swelling and rash), fatigue/weakness, thrombocytopenia, alopecia and nausea (Investigators' Brochure; PI-88; 2009).
The aim of this randomised phase I/II trial was to determine the optimal dose schedule, safety and activity of PI-88 in combination with docetaxel and prednisolone.
patients and methods
Patients with chemotherapy-naive CRPC were eligible for this study. All patients had histologically confirmed metastatic adenocarcinoma of the prostate.
All patients had castrate levels of testosterone by either luteinizing hormone-releasing hormone (LH-RH) agonist or orchidectomy and rising PSA levels as defined by the Prostate Cancer Working Group criteria [11] .
Both asymptomatic and symptomatic patients were allowed. LH-RH agonists were continued throughout the trial. Oral antiandrogen treatment was ceased at least 4 weeks before enrolment if patients were on flutamide, nilutamide or cyproterone acetate and at least 6 weeks before enrolment for bicalutamide. All patients had to have demonstrated PSA and/or radiologic progression despite cessation of antiandrogen therapy. Other standard eligibility criteria included adequate bone marrow, hepatic and renal function.
The dose levels were chosen on the basis of the data for TAX PI-88 in the lung study (N. Pavlakis, personal communication). This was also a days1-4 schedule. A decision was made to trial, the days1-7 schedule, because of the short half-life of PI-88.
study design
The study comprised a phase I dose-escalation component to establish the maximum tolerated dose (MTD) of PI-88 at the dosing schedules: The phase I component of the study was planned to involve a two dose de-escalation steps if more than one-third of the patients developed doselimiting toxic effects (DLTs) ( Table 1 ). Once the MTD had been established for each schedule, patients were randomly assigned to receive either the 4-day schedule of PI-88 or the 7-day schedule of PI-88 for the phase II component.
Up to a maximum of 10 3-weekly treatment cycles of docetaxel were permitted and patients were allowed to continue PI-88 treatment until either toxicity or disease progression occurred. PI-88 was allowed to be continued alone if docetaxel was stopped due to toxicity. On the other hand, withdrawal of PI-88 treatment of >2 weeks due to toxicity required the cessation of PI-88 but patients could continue to receive docetaxel until disease progression or intolerable toxicity.
The primary objective of the randomised phase II component was to determine PSA response in patients with CRPC treated with docetaxel and prednisone in combination with PI-88. PSA response was defined as a reduction in serum PSA levels of at least 50%. The secondary objectives of this study were to evaluate radiologic response rate in patients with measurable disease, PSA, progression-free survival, and overall survival. Safety and tolerability was assessed using National Cancer Institute of Canada -Common Toxicity Criteria version 3. Quality of life was assessed with functional assessment of cancer therapy-prostate questionnaire. An Table 1 . DLTs observed in the lead-in safety phase I
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biomarker analysis
All biomarker assays were conducted using colorimetric enzyme-linked immunosorbent assays (ELISAs) using the NUNC MaxiSorp 96-well plate from In Vitro Technologies (Gladesville, New South Wales, Australia). All pretreatment and 6-8 week post-treatment serum samples were tested in duplicate and the mean value used in the analysis. Relevant absorbance was measured using a Synergy HT spectrophotometric multiwell plate reader (BioTek, Winooski, VT). Analyte concentrations were calculated from a polynomial regression curve of the assay standards fitted using KC4 software (BioTek).
To determine whether pretreatment and 6-8 week post-treatment biomarker levels were predictive of survival, patients were divided into two groups for the analysis of each marker: those with levels above median level and those with levels equal to or below median level.
The change in marker levels over the first 6-8 weeks of the biomarkers were also analysed for their potential to predict survival. For each biomarker, patients were divided into two groups on the basis of whether the marker level had decreased or increased.
IL-6 and VEGF measurements were carried out using the DuoSet ELISA development kits (catalogue numbers DY206 and DY293B, respectively) by R&D Systems, MN. OPN measurement was carried out using the Quantikine Human OPN Immunoassay kit (catalogue number DOST00) from R&D Systems. All materials and protocol are as specified in the product datasheet.
statistical analysis
On the basis of the previous thalidomide/docetaxel studies [12] and the TAX 327 study [1] , a PSA response rate of 60% was predicted for the PI-88/docetaxel combination. Allowing 32 subjects per arm for the randomised phase II component, this study would have had 90% efficacy to identify the most active regimen on the basis of predicted response rates of 60% and 75% for the two treatment arms. The response rate of 70% was on the basis of our previous PROTAT trial (a phase II trial of docetaxel, prednisolone and thalidomide in patients with androgen-independent prostate cancer) with a response rate of 71% [12] . We reduced the expected response rate on the basis of the larger randomised clinical trial, TAX 327, as a more realistic expected response rate, which was still likely to be a clinically meaningful.
Allowing for 10% dropout, target accrual was therefore 70 patients in the phase II component. A minimum of 12 patients were required for the phase I component, for a total of 82 patients. For purposes of outcome evaluation, both phase I and phase II component data were pooled. The biomarkers were subjected to univariate analysis and the Kaplan-Meier method was used to determine survival. Descriptive statistics were employed in the analysis of safety and toxicity end points.
results
Twenty-one patients were enrolled in the phase I component, which resulted in two recommended phase II schedules of PI-88. The first dose level in each of the two schedules was started simultaneously alternating at randomisation to the days 1-4 schedule or the days 1-7 schedule (cohorts 1 and 3).
Cohort 1 (190 days 1-4) was expanded to six patients, as there was one DLT. Because no further DLTs were seen, this was considered suitable to be used at a higher dose of 250 mg/d (cohort 2) in the days 1-4 schedule. This was also one of the doses selected for phase II.
In the weekly schedule, this was commenced as planned at 190 mg/d days 1-7 (cohort 3). It was expanded to include a further three patients as there was one DLT in the first three. Of the expanded cohort, there were a further three DLTs which was the trigger for a dose de-escalation to 130 mg/d days 1-7. This was completed and as there were no DLTs, this dose level was the second dose selected for phase II. Cohort 4 250 mg days 1-7 was abandoned.
A further 34 patients were randomly allocated to the study to evaluate these two schedules in the phase II component, either 130 mg days 1-7 or 250 mg days 1-4.
A total of 56 patients were enrolled in this study before the trial was stopped early by the Safety Data Review Board due to a higher-than-expected febrile neutropenia rate of 27%. No significant difference was noted in febrile neutropenia rate between the two treatment arms. Granulocyte colonystimulating factor was not approved in Australia for febrile neutropenia in this setting.
The 56 patients enrolled in this study encompassed 21 patients from the phase I trial and 35 (of the planned 64) from the phase II component. However, 55 patients were assessable for toxicity and 50 patients were assessable for response.
The baseline characteristics of the patients are shown in Table 2 . Five patients could not be evaluated for response for various reasons (ineligible PSA values, lost to follow-up). One patient withdrew consent before commencing treatment and is not included in either of the analyses.
Due to the early study closure, we are not comparing data between the two dose schedules but will present outcomes as a pooled population. Median age for the overall population was 70 years (range 53-84 years). Median baseline PSA was 151 ng/ml (0.2-2000 ng/ml) and median Gleason score was 8 (range 6-10). Metastases were present in bone, lymph nodes and liver in 80%, 26% and 7%, respectively. In the pooled population, a ‡50% reduction in PSA was seen in 70% of patients (Table 3) . Median survival was 61 weeks (with a range of 6-99 weeks), and 1-year survival was 71% (Figure 1 ). toxicity Recruitment to the trial was stopped early by a Safety Data Review Board due to a higher-than-expected febrile neutropenia rate of 27%. Grade 3 dehydration, fatigue, diarrhoea, nausea and thrombocytopenia were seen in 11%, 16%, 6%, 16% and 22%, respectively. One patient developed a pulmonary embolus and one patient had a middle cerebral artery infarct. The most common grade 1-2 toxic effects were fatigue, alopecia and nausea. Grade 1-2 peripheral neuropathy occurred in 24% of patients (Table 4) .
It was felt that certain toxic effects were more likely due to docetaxel, particularly fatigue and nail changes. On that basis, 19 patients ceased docetaxel and were still responding and so continued PI-88 for various durations.
biomarkers
Serum was obtained at two points: first from 52 patients at baseline (four patients withdrew) and the second time was at 6-8 weeks from enrolment, serum was obtained from 36 patients.
Exploratory univariate analyses of all potential biomarkers showed an increase rather than a predicted decrease in VEGF, from before treatment to 6-8 week after treatment, trending original article Annals of Oncology towards being predictive for survival (P = 0.056) (Figure 2 ). CRP analysis showed that both the pretreatment level (P = 0.026) and the 6-8 week post-treatment level (P = 0.005) were predictive for survival, although the change from before treatment to 6-8 week after treatment (P = 0.999) was not (Figures 3 and 4) . IL-6 on the other hand showed that the pretreatment level was not prognostic for survival (P = 0.5111), while the 6-8 week level (P = 0.0008) and the change in IL-6 from before treatment to the 6-8 week after treatment (P = 0.0020) were prognostic. Similarly, the PSA level at 6-8 weeks was predictive for survival (P = 0.0497) although the pretreatment level was not (P = 0.2468). OPN was not prognostic for survival at before treatment or at 6-8 weeks after treatment. These data need to be interpreted with caution due to the small number of patients. The study was terminated prematurely before reaching its target accrual due to higher-than-expected febrile neutropenia incidence, 27% compared with only 3% febrile neutropenia reported in TAX 327 [1] . The reasons for this observation are not clear but may include issues to do with patient selection and/or an interaction between PI-88 and docetaxel. The number of patients analysed was too small to identify differences between the two arms of the study as far as toxicity or response were concerned. Overall, however, there were no distinct differences between the arms in either response or toxicity.
Firm conclusions regarding activity of the combined regimen cannot be made on the limited data available. Nevertheless, these findings contribute to our understanding of CRPC management. The data from the 56 patients enrolled in this study provide insight into the toxicity profile of PI-88 in combination with docetaxel chemotherapy.
Optimal phase I/II trial design is an evolving area in the integration of biologic agents in combination with cytotoxic therapies. Unexpectedly, high rates of toxicity have been previously reported with combination of cytotoxic and antiangiogenic agents [13] . The mechanism of increased myelosuppression is not clear from this study. This group of patients was similar to large randomised trials of patients with CRPC as far as inclusion criteria were concerned. Assuming that the therapeutic activity of PI-88 lies mainly in its antiangiogenic effects, it is possible that the unacceptable myelotoxicity might be related to synergistic effect with the docetaxel on the bone marrow. However, this was not seen when PI-88 was combined with dacarbazine in patients with melanoma where the toxicity was mainly injection site bruising [14] . Lower rates of febrile neutropenia were seen in patients receiving this agent in combination with weekly docetaxel in lung cancer (N. Pavlakis, personal communication).
In this study, a higher percentage of patients achieved a ‡50% PSA decline in comparison with historical controls [1, 2] . However, median survival was worse than what we have seen in most docetaxel alone studies.
There are ongoing issues regarding the reliability of PSA as a surrogate marker in CRPC. Phase II trials are limited by this as an end point while standard RECIST criteria are not appropriate for this patient group. The reliability of PSA in the context of PI-88 is less well understood.
Demographic factors were similar to the other studies; however, a possible explanation for the discrepancy between PSA response and survival is that the study population was a less healthy group. This highlights the difficulties in phase II trials in this patient group and reinforces the importance of overall survival as a primary end point; however, this is likely to be even more complicated in the era of second-and third-line options.
Our exploratory predictive biomarker analyses can only be hypothesis generating due to small sample size and the multiple statistical comparisons. Nevertheless, the data concerning CRP and IL-6 as potential predictors for outcome are intriguing and have relevance for antiangiogenic approaches. Findings from other studies carried out in larger patient groups show similar results. In a study of 160 androgen-independent prostate cancer patients receiving docetaxel-based therapy, Beer et al. [15] found pretreatment plasma CRP levels to be a strong predictor of poor survival . Similarly, in a study of 197 patients with metastatic hormone refractory prostate cancer, George et al. [16] showed that elevated pretreatment plasma IL-6 levels were significantly prognostic. On the basis of the findings of these and other similar studies, further prospective analyses are required in future trials to identify any potential role for these factors as predictors of response or potential for selection of patients most likely to benefit from such combinations.
A 3 -weekly regimen of docetaxel is currently the accepted standard of care for CRPC. In view of the documented increased angiogenesis associated with progressive CRPC, targeting this process may be an important mechanism to improve outcomes of patients with CRPC. A number of other trials are currently accruing patients to evaluate the efficacy of combining these agents with a standard 3-weekly docetaxel regimen. Consideration of approaches to improve the toxicity profile of the schedule used in this study include modification 
conclusions
The regimen of docetaxel and PI-88 shows activity in metastatic CRPC, but the treatment schedule used in this study was associated with unexpectedly high levels of myelosuppression. Further evaluation of different scheduling and dosing of PI-88 with docetaxel or support with growth factors may be warranted to optimise efficacy with a more manageable sideeffect profile. CRP and IL-6 appear to have some potential as prognostic markers in CRPC, and should be further evaluated. Dose-limiting toxic effects mandated de-escalation from cohort 3. The resulting de-escalation cohort replaced cohort 4 (see Table 1 ). 
